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Abstract 
The purpose of this study was to evaluate the biopharmaceutical and physicochemical drug properties 
suitable for orally disintegrating tablets (ODTs). The molecular weight (MW), polar surface area (PSA), 
hydrogen bond donor (HBD) and acceptor (HBA) numbers, net charge at pH 7.4, log D6.5, the highest dose 
strength, solubility in water, dose number, and elimination t1/2 of 57 ODT drugs and 113 drugs of 
immediate-release (IR) formulations were compared. These drugs were classified according to the 
Biopharmaceutical Classification System (BCS). A lower dose strength and a longer elimination t1/2 have 
been observed as characteristic properties of ODTs. The proportion of basic drugs was higher in the ODTs 
than in the IR formulations. A significant difference was not observed between the ODT and the IR 
formulation for MW, PSA, HBD, HBA, log D6.5, solubility in water, and dose number. The distributions of the 
ODTs and IR formulations among each BCS class were similar, suggesting that an ODT can be developed 
regardless of the BCS class of a drug. 
Keywords 
orally disintegrating tablet (ODT); bioequivalence; biopharmaceutics classification system (BCS). 
 
Introduction 
An orally disintegrating tablet (ODT) improves patient compliance because it can be taken without 
water, does not cause dysphagia, and can prevent patients from spitting out their medication [1,2]. Many 
pharmaceutical companies are working on the development of ODTs. An ODT should be bioequivalent to a 
corresponding standard formulation, e.g. an immediate-release (IR) formulation. An ODT disintegrates and 
dissolves rapidly in the oral cavity within 30 seconds. Therefore, the dissolution rate may differ significantly 
between ODTs and IR formulations. When the dissolution rates are different between the ODT and the IR 
formulation, the risk to fail in a bioequivalence (BE) study is high. Therefore, during the development of an 
ODT, it is important to assess the risk of failing in a clinical BE study. It is preferable to reduce the risk of 
failing a clinical BE study because such studies are expensive, time consuming, and a burden to healthy 
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volunteers. 
However, there has been no research investigating the biopharmaceutical properties of drugs suitable 
to be an ODT. In the present study, several physicochemical and biopharmaceutical properties were 




The physicochemical and biopharmaceutical properties of drugs marketed as ODTs and IR formulations 
were compared in this study. Currently, the number of drugs developed as ODT is largest in Japan. In 
addition, all the ODT formulations approved in Japan were proved to be bioequivalent to the IR formulation 
with and without water intake. Therefore, the ODT formulations in Japanese market were selected in this 
study. The list of the ODT drugs was obtained from the Pharmaceuticals and Medicinal Devices Agency 
website (http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html) (Supplement Table 1). The 
list of the IR formulations were selected from the top 200 pharmaceutical products in Japan (Supplement 
Table 2) [3]. Finally, 57 compounds for the ODT and 113 compounds for the IR formulation were selected 
and analysed. The 25 compounds were overlapping between the lists of the ODTs and IR formulations. 
Biopharmaceutical drug properties 
The physicochemical and biopharmaceutical properties of drugs related to the formulation design and 
oral bioavailability were selected [4,5]. The molecular weight (MW), polar surface area (PSA), hydrogen 
bond donor (HBD) and acceptor (HBA) numbers, dissociation constants (pKa), and n-octanol/water 
distribution coefficients at pH6.5 (log D6.5) were calculated using ACD Percepta (ACD/Labs Software V 14.0.0 
(http://www.acdlabs.com/products/percepta/predictors.php)). The calculated pKa and log D were used for 
all drugs, as the experimental values were not available for some drugs. 
Net charge (NC) at pH 7.4 was represented as the weighted sum of the charge of each species.  
NC = (±0) ∙ 𝑓0 + (+1) ∙ 𝑓+ + (−1) ∙ 𝑓− + (+2) ∙ 𝑓++ + ⋯  (1) 
(𝑓0 + 𝑓+ + 𝑓− + 𝑓++ + ⋯ = 1) 
where f0 is the fraction of the undissociated species, f+ is that of +1 charged species, etc. Each fraction 
was calculated by the pKa and the pH (set to be 7.4 in this study) using the Henderson-Hasselbalch equation 
[6]. The NC equations for acids and bases containing up to three ionization centers are summarized in 
Supplement Table 3. When a drug was more than 50 % dissociated at pH 7.4, it was classified as an acid (NC 
< -0.5) or as a base (NC > 0.5). Log D was calculated at pH 6.5 to estimate the permeability, whereas NC was 
calculated at pH 7.4 to discuss the pharmacokinetics after the absorption. The solubility in water, the 
highest dose strength, and the elimination t1/2 were obtained from the prescription information. When a 
reliable solubility figure was unavailable, a solubility value was assigned based on the solubility category 
defined by the Japanese pharmacopeia (Supplement Table 4).  
Provisional classification according to the Biopharmaceutical Classification System 
According to the Biopharmaceutical Classification System (BCS), drugs can be categorized into the four 
classes, i.e. high solubility/high permeability (class I), low solubility/high permeability (class II), high 
solubility/low permeability (class III), and low solubility/low permeability (class IV). Moreover, BCS class II 
drugs can be sub-classified into acid (class IIa), base (class IIb), and undissociated drugs (class IIc) [7]. 
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In the previous studies, solubility in water and calculated log D6.5 were used as the surrogates of 
solubility and permeability data to provide provisional BCS class [3,8]. The same approach was taken in this 
study. According to the official BCS guidance, the equilibrium solubility of a drug at the physiological 
gastrointestinal pH range (namely, pH 1.2 to pH 6.8 or 7.4) is required. However, the pH solubility profile 
data were not available for many drugs. Therefore, solubility in water reported in the prescription 
information was used in this study. The dose number (Do) is a dimensionless number expressed by the ratio 




  (2) 
where S is the solubility of a drug in water, V is the intestinal fluid volume (set to be 250 mL in this study), 
and M is the highest dose strength. Drugs were defined as highly soluble when the Do was ≤ 1.  
According to the official BCS guidance, to classify the permeability category, the fraction of a dose 
absorbed (Fa%) in humans or Caco-2 permeability data is required. However, due to the limited availability 
of these data, the permeability was classified based on the calculated log D6.5 in this study. The log D6.5 
value of metoprolol was chosen as the criteria for high permeability [Fa% in human, 95 % [9]; human 
effective permeability, 1.26 × 10-4 cm/s [9]; log D6.5, -0.92 (ACD Percepta)].  
Statistical analysis 
A student’s t-test was used to evaluate the significance of difference between the ODTs and IR 
formulations in MW, PSA, HBD, HBA, NC at pH 7.4, log D6.5, the highest dose strength, solubility in water, 
Do, and elimination t1/2. One-way analysis of variance was used to evaluate the significance of difference 
between acids, bases, and undissociated drugs in elimination t1/2 for the ODTs and IR formulations, 
respectively. A minimum p value of 0.05 was used as the significance level for all tests. Microsoft Excel 2010 
(Microsoft) was used for statistical analysis. 
Results 
MW of free form, PSA, HBD, HBA, NC at pH 7.4, log D6.5, the highest dose strength, solubility in water, 
Do, and elimination t1/2 are shown in Table 1.  Some calculated pKa and log D6.5 might have a margin of error 
about 1 log unit (e.g. pKas of cetirizine (6.7 (B); 7.7 (B) [10]), domperidone (9.0 (B); 7.1 (B) [10]), glimepiride 
(5.1 (A); 6.2 (A) [11]), log D6.5 of famotidine (-2.14; -1.3 [11]), glimepiride (1.51; 3.0 [11]) (calculated values; 
experimental values).  
NC at pH 7.4 was significantly higher in the ODT than that for the IR formulation (p = 0.02) (Figure 1e). 
The percentages of acid, base, and undissociated drugs for the ODTs were 13, 41 and 45 %, respectively 
(2 % unclassifiable). The corresponding percentages in the IR formulations were 30, 30 and 38 %, 
respectively (2 % unclassifiable). The highest dose strength of the ODTs was significantly lower than that of 
the IR formulations (p = 0.01) (Figure 1g). The medians of the highest dose strength in the ODTs and IR 
formulations were 10 mg and 30 mg, respectively. The maximum values of the highest dose strength in the 
ODTs and IR formulations were 200 mg and 900 mg, respectively (Table 2). The elimination t1/2 of the ODTs 
tended to be longer than that of the IR formulations (p = 0.07) (Figure 1j). The medians of t1/2 in the ODTs 
and IR formulations were 6.7 h, and 3.3 h, respectively (Table 2). A significant difference was not observed 
between the ODTs and the IR formulations for MW, PSA, HBD, HBA, log D6.5, solubility in water, and Do 
(Figure 1a, b, c, d, f, h, i). 
The distribution of the ODTs and IR formulations among each BCS class were similar (Figure 2). The 
percentages of BCS class I, class II, class III, and class IV for the ODT were 52, 29, 20 and 0 %, respectively 
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(2 % unclassifiable). The corresponding percentages for the IR formulation were 48, 30, 16 and 4 %, 
respectively (2 % unclassifiable). The distribution of BCS II subclass was also similar (Figure 2). The 
percentages of BCS class IIa, class IIb, and class IIc for the ODT were 7, 12 and 9 %, respectively, whereas 
the corresponding percentages for the IR formulation were 10, 10 and 11 %, respectively. 
 
  
Figure 1. Box and whisker plots of biopharmaceutical properties of ODT and IR formulation drugs ; the 
bottom and top of the box are the first and third quartiles, the band inside the box is the median, and the 
ends of the whiskers are the minimum and maximum.  (a) MW of free form. (b) Polar surface area. (c) 
Hydrogen bond donor number. (d) Hydrogen bond acceptor number.  (e) Net charge at pH 7.4. (f) Log D6.5. (g) 
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 646 321 14 19 0.0 – -4.88 100 1429 0.00028 3.2 3 
Acetaminophen 151 49 2 3 0.0 – 0.40 500 10 0.2 2.9 1 
Acetylsalicylic acid 180 64 1 4 -1.0 3.5 (A) -1.39 100 3.33 0.12 0.4 3 
Acyclovir 225 115 4 8 0.0 – -1.23 400 1 1.6 2.4 4 
Alendronate sodium hydrate 249 181 7 8 -2.0 
1.7 (A), 2.7 (A),  
6.1 (A), 10.3 (B) 
-8.44 35 25.6 0.00546 1.5 3 
Alfacalcidol 401 40 2 2 0.0 – 7.58 0.03 0.01 0.0012 17.6 1 
Allopurinol 136 66 2 5 0.0 – -0.70 100 0.1 4 1.6 2 
Ambroxol hydrochloride 378 58 4 3 1.0 8.7 (B) 0.48 45 26.8 0.00672 11.2 1 
Amlodipine besylate 409 100 3 7 1.0 9.0 (B) 1.09 10 2.22 0.018 36.2 1 
Aripiprazole 448 45 1 5 0.6 7.7 (B) 4.42 24 0.01 9.6 59.6 2 
Atenolol 266 85 4 5 1.0 9.4 (B) -2.53 50 1 0.2 10.8 3 
Atorvastatin calcium 559 112 4 7 -1.0 4.3 (A) 2.06 10 0.145 0.276 10.8 1 
Azithromycin hydrate 749 180 5 14 1.8 8.2 (B), 8.6 (B) -0.19 600 0.01 240 61.9 2 
Azulene sulfonate sodium hydrate 278 63 1 3 -1.0 1.7 (A) -2.03 2 10 0.0008 2.45 3 
Benidipine hydrochloride 506 114 1 9 0.8 8.0 (B) 3.54 8 0.01 3.2 1.0 2 
Bepotastine besylate 389 63 1 5 0.0 4.4 (A), 8.9 (B) 0.86 10 23.3 0.00172 2.5 1 
Beraprost sodium 398 87 3 5 -1.0 4.8 (A) 1.42 0.04 833 1.92 × 10
-7
 1.1 1 
Bicalutamide 430 116 2 6 0.0 – 2.53 80 0.01 32 4.9 2 
Bisoprolol fumarate 325 60 2 5 1.0 9.4 (B) -0.55 5 1250 1.6 × 10
-5
 8.6 1 
Brotizolam 394 71 0 4 0.0 – 2.80 0.25 0.01 0.1 7 1 
Cabergoline 452 72 2 7 1.0 9.4 (B) 0.40 1 0.01 0.4 43 1 
Camostat mesylate 398 137 4 9 1.0 9.1 (B) -0.53 100 45. 5 0.0088 1.7 1 
Candesartan cilexetil 440 119 2 9 -2.0 2.1 (A), 4.2 (A) 0.29 12 0.01 4.8 2.2 2 
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Carvedilol 406 76 3 6 0.9 8.2 (B) 2.20 20 0.01 8 7.7 2 
Cefcapene pivoxil hydrochloride 594 257 3 16 0.0 5.9 (A), 9.0 (B) -1.59 100 1.88 0.213 1.1 3 
Cefdinir 395 212 5 10 -1.0 2.8 (A) -3.92 100 0.381 1.05 1.6 4 
Cefditoren pivoxil 621 257 3 13 -0.2 8.1 (A) 2.45 100 0.01 40 1.1 2 
Cefotiam hexetil hydrochloride 696 276 3 16 0.8 8.0 (B) -0.14 200 1000 0.0008 0.8 1 
Cetirizine hydrochloride 389 53 1 5 -0.8 3.5 (A), 6.7 (B) -0.09 10 1000 4.0 × 10
-5
 7.5 1 
Cilostazol 369 82 1 7 0.0 – 3.01 100 0.01 40 10.1 2 
Clarithromycin 748 183 4 14 0.9 8.2 (B) 1.56 200 0.01 80 4.4 2 
Cyclosporin a 1203 279 5 23 0.0 – 1.80 50 3.38 0.0592 1.6 1 
Desmopressin acetate hydrate 1069 486 18 26 0.0 – -7.34 0.24 33 2.9 × 10
-5
 2 3 
Diclofenac sodium 296 49 2 3 -1.0 4.2 (A) 2.17 25 17.2 0.0058 1.2 1 
Dienogest 311 61 1 3 0.0 – 2.64 1 0.01 0.4 8.0 1 
Domperidone 426 68 2 7 1.0 9.0 (B) 2.26 10 0.01 4 0.9 2 
Donepezil hydrochloride 379 39 0 4 1.0 8.8 (B) 1.97 10 10 0.004 70.7 1 
Doxazosin mesylate 451 112 2 10 0.1 6.5 (B) 1.20 4 1 0.016 11.8 1 
Doxifluridine 246 99 3 7 -0.4 7.6 (A) -1.13 200 33 0.0242 0.8 
f
 3 
Droxidopa 213 124 6 6 -0.1 2.1 (A), 8.3 (B) -3.57 200 2.4 0.333 2 3 
Ebastine 470 30 0 3 0.9 8.2 (B) 5.49 10 0.01 4 17.6 2 
Enalapril maleate 376 96 2 7 -1.0 3.1 (A) -1.06 10 21 0.00191 6.1 3 
Epalrestat 319 115 1 4 -1.0 3.6 (A) -1.04 50 0.009 22.2 1.8 4 
Eperisone hydrochloride 259 20 0 2 0.9 8.5 (B) 2.02 50 200 0.001 1.6 1 
Epinastine hydrochloride 249 42 2 3 1.0 12.0 (B) 0.77 20 133 0.0006 9.2 1 
Ethyl icosapentate 331 26 0 2 0.0 – 6.65 900 0.01 360 58.9 2 
Etizolam 343 71 0 4 0.0 – 2.87 1 0.01 0.4 6.3 1 
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Famotidine 337 238 8 9 0.8 7.9 (B) -2.14 20 0.741 0.108 3.1 3 
Fexofenadine hydrochloride 502 81 3 5 0.0 4.4 (A), 9.4 (B) 2.43 60 1.43 0.168 19 1 
Fluconazole 306 82 1 7 0.0 – 0.70 400 1 1.6 30 2 
Flurbiprofen 244 37 1 2 -1.0 4.1 (A) 1.48 40 0.01 16 2.7 2 
Fluvastatin sodium 411 83 3 5 -1.0 4.3 (A) 1.33 30 82.0 0.00146 1.3 1 
Fluvoxamine maleate 318 57 2 4 1.0 9.4 (B) 0.36 75 14 0.0214 14.1 1 
Fursultiamine 399 152 3 7 0.0 – 2.05 50 200 0.001 14.7 1 
Galantamine hydrobromide 287 42 1 4 0.8 7.9 (B) 0.12 12 33 0.00145 6.8 1 
Gefitinib 447 69 1 7 0.3 7.0 (B) 3.07 250 0.01 100 30.1 2 
Gimeracil 146 53 2 3 0.1 6.5 (A), 12.6 (B) -2.58 7.25 1.74 0.0167 3 3 
Glimepiride 491 133 3 9 -1.0 5.1 (A) 1.51 3 0.01 1.2 5.8 2 
Granisetron hydrochloride 312 50 1 5 1.0 10.5 (B) -0.95 2 588 1.36 × 10
-5
 5.3 3 
Hydrochlorothiazide 298 135 4 7 0.0 – 0.01 12.5 0.1 0.5 9.1 1 
Imatinib mesylate 494 86 2 8 0.6 7.6 (B) 2.00 200 1300 0.000615 15.9 1 
Imidafenacin 319 61  2 4 0.6 7.6 (B) 1.68 0.1 0.01 0.04 3.1 1 
Imidapril hydrochloride 405 116  2  9  -1.0 2.4 (A) -2.51 10 49.3 0.000812 1.7 3 
Irsogladine maleate 359 96  1 6 0.0 – 1.81 4 0.01 1.6 128 2 
Itraconazole 706 101  0  12  0.1 6.5 (B) 4.67 200 0.01 80 27.9 2 
Ketoprofen 254 54  1  3  -1.0 4.2 (A) 0.87 75 0.01 30 1.6 2 
Ketotifen fumarate 309 49  0  2  1.0 8.8 (B) 1.79 1 1 0.004 6.7 1 
L-carbocysteine 179 126  4  5  -1.0 
2.1 (A), 3.8 (A),  
8.8 (B) 
-3.80 500 0.1 20 1.6 4 
Lafutidine 432 104  1 7 0.4 7.2 (B) 0.56 10 0.01 4 1.6 2 
Lansoprazole 369 87  1 5 0.0 – 2.40 30 0.0323 3.72 1.4 2 
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Levofloxacin 361 73  1  7  -0.5 5.2 (A), 7.4 (B) -1.76 500 16. 7 0.12 7.9 3 
Limaprost alfadex 366 95  3  5  -1.0 4.6 (A) 0.85 0.005 370 5.4 × 10
-8
 0.5 1 
Loratadine 383 42  0  4  0.0 – 5.32 10 0.00303 13.2 20.1 2 
Losartan potassium 423 93  2  7  -1.0 4.2 (A) 1.77 100 1000 0.0004 1.8 1 
Loxoprofen sodium hydrate 246 54  1  3  -1.0 4.4 (A) 0.37 60 1000 0.00024 1.2 1 
Manidipine hydrochloride 611 117  1  10  0.1 6.1 (B) 5.29 20 3.88 0.0206 1.5 1 
Mecobalamin 1344 ND ND ND – ND ND 0.5 12.5 0.00016 12.5 UC 
Meloxicam 351 136  2  7  -1.0 4.5 (A) 0.29 10 0.01 4 27.6 2 
Memantine hydrochloride 179 26  2 1 1.0 10.8 (B) 0.40 20 33 0.00242 53.6 1 
Menatetrenone 445 34  0  2  0.0 – 9.55 15 0.01 6 3.9 2 
Mesalazine 153 84  4  4  -1.0 1.9 (A) -1.85 500 1 2 6.4 4 
Methylmethionine sulfonium chloride 164 ND ND ND – ND ND 25 1000 0.0001 3.2 UC 
Mexiletine hydrochloride 179 35  2  2  0.9 8.6 (B) 0.39 100 833 0.00048 9.4 1 
Midodrine hydrochloride 254 94  4 6 0.7 7.8 (B) -1.24 2 138 5.80 × 10
-5
 2.4 3 
Miglitol 207 104  5 6 0.1 6.5 (B) -2.27 75 791 0.000379 2.0 3 
Montelukast sodium 586 96  2  4  -1.0 4.8 (A) 5.82 10 200 0.0002 4.3 1 
Mosapride citrate hydrate 422 77  3  6  0.1 6.2 (B) 2.89 5 0.01 2 2 2 
Naftopizil 393 45  1 5 0.2 6.9 (B) 3.65 75 0.01 30 11.2 2 
Nicardipine hydrochloride 480 114  1  9  0.4 7.3 (B) 3.94 20 6 0.0133 1.5 1 
Nicergoline 484 57  0  6  0.1 6.3 (B) 4.29 5 0.01 2 3.3 2 
Nicorandil 211 97  1  7  0.0 – 0.93 5 10 0.002 0.8 1 
Nifedipine 346 110  1  8  0.0 – 3.45 10 0.01 4 1.0 2 
Nilvadipine 385 134  1  9  0.0 – 3.23 4 0.01 1.6 10.7 2 
Nizatidine 331 140  2  7  0.5 7.3 (B) -0.61 150 17.3 0.0347 1.7 1 
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Olanzapine 312 56  1  4  1.0 10.4 (B) -0.35 10 0.01 4 30.6 2 
Olopatadine hydrochloride 337 50  1  4  0.0 4.3 (A), 9.2 (B) 1.54 5 10 0.002 0.8 1 
Ondansetron 293 40  0 4 0.6 7.5 (B) 1.76 4 0.01 1.6 4.5 2 
Oseltamivir phosphate 312 91  3  6  1.0 8.8 (B) -0.19 75 521 0.000576 7 1 
Oteracil potassium 157 108  3 7 -1.0 -3.1 (A) -5.54 24.5 7.42 0.0132 3 3 
Paroxetine hydrochloride hydrate 329 40  1  4  1.0 9.7 (B) 0.84 20 2 0.04 13.6 1 
Pergolide mesylate 314 44  1  2  0.8 8.0 (B) 2.39 0.25 5 0.0002 8.8 1 
Perindopril erbumine 368 96  2  7  -1.0 3.2 (A) 0.07 4 500 3.2 × 10
-5
 0.8 1 
Pilsicainide hydrochloride hydrate 272 32  1  3  1.0 10.4 (B) -0.12 50 100 0.002 4.4 1 
Pioglitazone hydrochloride 356 94  1  5  -0.9 6.3 (A) 2.16 30 0.01 12 6.7 2 
Pitavastatin calcium 421 91  3 5 -1.0 4.2 (A) 1.17 4 0.1 0.16 9.3 1 
Polaprezinc ND ND ND ND – ND ND 75 0.01 30 2.2 UC 
Pramipexole hydrochloride hydrate 211 79  3 3 1.0 9.5(B) -1.03 0.5 1000 2.0 × 10
-6
 8.4 3 
Pranlukast hydrate 482 119  2  9  -1.0 5.3 (A) 2.74 112.5 0.0012 375 1.2 2 
Pravastatin sodium hydrate 425 124  4  7  -1.0 4.3 (A) 0.06 10 100 0.0004 2.7 1 
Procaterol hydrochloride 290 82  4  5  1.0 9.4 (B) -1.47 0.05 50 4.0 × 10
-6
 3.8 3 
Propiverine hydrochloride 367 39  0  4  0.7 7.8 (B) 4.10 20 124 0.000645 10.7 1 
Quetiapine fumarate 384 74  1  5  0.2 6.7 (B) 1.92 200 3.38 0.2364 3.5 1 
Ramosetron hydrochloride 279 51  1 4 0.4 7.3 (B) 1.80 0.005 575 3.48 × 10
-8
 7 1 
Ranitidine hydrochloride 314 112  2  7  0.9 8.4 (B) -1.47 150 1429 0.00042 2.7 3 
Rebamipide 371 96  3  6  -1.0 3.4 (A) -0.75 100 0.006 66.7 1.9 2 
Risedronate sodium hydrate 283 168  5  8  -3.0 
1.4 (A), 2.4 (A),  
6.0 (A) 
-8.38 75 33 0.00909 1.5 3 
Risperidone 410 62  0  6  0.8 8.1 (B) 0.99 2 0.01 0.8 0.3 1 
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Rizatriptan benzoate 269 50  1 5 1.0 9.5 (B) -0.70 10 34 0.00118 1.7 1 
Sarpogrelate hydrochloride 430 85  1  7  -0.2 4.3 (A), 8.1 (B) 1.37 100 1 0.4 0.8 1 
Selegiline hydrochloride 187 3  0 1 0.6 7.5 (B) 1.81 2.5 1667 6.0 × 10
-6
 5.3 1 
Sertraline hydrochloride 306 12  1 1 1.0 9.5 (B) 2.45 100 2.70 0.148 25.1 1 
Sildenafil citrate 475 118  1 10 0.0 – 1.85 50 1 0.2 1.6 1 
Simvastatin 419 73  1  5  0.0 – 4.60 20 0.01 8 2.3 2 
Solifenacin succinate 362 171  5 12 1.0 9.0 (B) 1.36 5 610 3.28 × 10
-5
 46.5 1 
Sultamicillin tosilate 595 216  3  13  0.2 6.8 (B) -0.46 375 0.1 15 1.0 2 
Tacrolimus hydrate 804 178  3  13  0.0 – 4.10 5 0.01 2 32.0 2 
Taltirelin hydrate 405 171  5  12  0.2 6.7 (B) -2.73 5 208 9.6 × 10
-5
 2 3 
Tamoxifen citrate 372 12  0  2  1.0 8.7 (B) 4.68 20 0.09 0.889 27.2 1 
Tamsulosin hydrochloride 409 108  3 7 1.0 8.8 (B) -0.06 0.2 11.8 6.76 × 10
-5
 11.7 1 
Tegafur 200 59  1  5  -0.4 7.6 (A) -0.43 25 16.8 0.00595 1.9 1 
Temocapril hydrochloride 477 149  2  7  -1.0 3.7 (A) 0.62 4 0.719 0.0223 0.2 1 
Teprenone 331 17  0  1  0.0 – 7.40 50 8.32 0.0240 1.8 1 
Terbinafine hydrochloride 291 3  0  1  0.2 6.9 (B) 5.45 125 5.07 0.0987 6.2 1 
Ticlopidine hydrochloride 264 31  0  1  0.3 7.1 (B) 3.41 100 58.8 0.0068 1.6 1 
Tocopherol nicotinate 536 48  0  4  0.0 – 11.14 200 0.01 80 4.3 2 
Tramadol hydrochloride 263 33  1 3 1.0 9.6 (B) -0.18 50 100 0.002 5.7 1 
Tulobuterol hydrochloride 228 32  2  2  1.0 9.6 (B) -0.17 1 714 5.6 × 10
-6
 3.2 1 
Ursodeoxycholic acid 393 78  3  4  -1.0 4.8 (A) 2.01 100 0.01 40 1.1 2 
Valacyclovir hydrochloride 324 147  5  10  0.7 7.8 (B) -1.78 500 100 0.02 3.0 3 
Valproate sodium 144 37  1  2  -1.0 4.8 (A) 0.97 200 1000 0.0008 9.5 1 
Valsartan 436 112  2  8  -2.0 3.6 (A), 4.2 (A) -0.71 160 0.17 3.76 7.7 2 
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Voglibose 267 154  8  8  0.2 6.8 (B) -3.57 0.3 1000 1.2 × 10
-6
 5.3 3 
Zolmitriptan 287 57  2 5 1.0 9.5 (B) -0.29 2.5 0.1 0.1 2.9 1 
Zolpidem tartrate 307 38  0  4  0.2 6.8 (B) 2.78 10 8.9 0.00449 1.9 1 
Zonizamide 212 95  2 5 0.0 – 0.45 25 0.270 0.37 119.1 1 
ND = no data. 
UC = unclassifiable. 
a
 Net charge at pH 7.4 calculated by Eq. 1. 
b
 Calculated value (ACD/Labs Software V 14.0.0). 
c
 Data from prescription information (Supplement Tables 1 and 2) otherwise noted. 
d
 Underscored drugs correspond to ODTs. 
e
 Drugs in italics correspond to IR formulations. 
f
 Reference [12] 
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Table 2. Minimum, maximum, and median of biopharmaceutical properties of ODT and IR 
formulation drugs. 
Biopharmaceutical properties ODT IR formulation 
MW of free form 
n 56 113 
Median 359 371 
Min. – Max. 146 – 1069 136 – 1344 
PSA 
n 56 111 
Median 70 84 
Min. – Max. 3 – 486 3 – 321 
HBD 
n 56 111 
Median 1 2 
Min. – Max. 0 – 18 0 – 14 
HBA 
n 56 111 
Median 5 6 
Min. – Max. 1 – 26 1 – 23 
NC a pH 7.4 
n 56 111 
Median 0.2 0.0 
Min. – Max. -2.0 – 1.0 -3.0 – 1.8 
Log D6.5 
n 56 111 
Median 1.02 0.97 
Min. – Max. -7.34 – 5.49 -8.44 – 11.14 
The highest dose 
strength 
(mg) 
n 57 113 
Median 10 30 
Min. – Max. 0.005 – 200 0.003 – 900 
Solubility in water 
(mg/mL) 
n 57 113 
Median 1.43 3.33 
Min. – Max. 0.003 – 1667 0.0012 – 1429 
Do 
n 57 113 
Median 0.1 0.04 
Min. – Max. 3.48 × 10-8 – 66.7 5.4 × 10-8 – 375 
Elimination t1/2 
(h) 
n 57 113 
Median 6.7 3.3 
Min. – Max. 0.9 – 128 0.2 – 70.7 
a
 Net charge at pH 7.4 calculated by Eq. 1. 
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Discussion 
A significant difference was seen in the highest dose strength between the ODT and IR formulation. The 
ODT would have to have a feasible tablet size and drug loading [13,14]. Therefore, a drug with a high dose 
strength (>200 mg) would be less suitable an ODT.  
There was no significant difference in the solubility in water and Do between the ODT and IR 
formulation. This result suggests that many drugs can be developed as an ODT regardless of their solubility 
and Do (e.g., bicalutamide: S = 0.01 mg/mL, Do = 32, cilostazole: S = 0.01 mg/mL, Do = 40). Furthermore, an 
ODT shows BE with a corresponding IR formulation with and without water intake. Therefore, even though 
it is counterintuitive, water intake may have little effect on the dissolution and oral absorption of low 
solubility drugs. Previously, Sumesen et al. reported that the oral absorption of danazol was not 
significantly altered when administered together with 1000 mL of water compared to when administered 
with 200 mL [15]. Danazol, which has poor water solubility (0.2 g/mL) and high permeability (log D6.5 = 
4.5), is a typical BCS class II drug [16].  
The drugs that have been developed as ODTs tended to have a longer elimination t1/2. Previously, we 
reported that the elimination t1/2 of drugs influence the BE of Cmax [17]. For the drugs with high permeability 
and short elimination t1/2, BE of Cmax between two formulations with different dissolution rates would 
become more difficult to prove. This point has been suggested by several articles [18-21]. A drug with a 
long elimination t1/2 might be suitable for an ODT. 
The proportion of bases was larger in the ODT than in the IR formulation. It is well known that the basic 
lipophilic drugs have a large distribution volume, and a long elimination t1/2 due to wide tissue distribution 
[22]. A significant difference was seen in elimination t1/2 between acids, bases, and undissociated drugs in 
the IR formulation (p = 0.04) (Figure 3). 
  
Figure 3. Box and whisker plot of elimination t1/2 of acid, base, and undissociated drugs 
The biowaiver schemes (BWS) has been discussed based on BCS proposed by Amidon et al. in 1995 [5]. 
In 2000, the US Food and Drug Administration (FDA) adopted the BCS-BWS [23]. The guideline allows BCS 
class I drugs which show rapid dissolution (>85 % dissolution in 30 min) to waive clinical BE studies. The 
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there are some differences among these guidelines, e.g. solubility pH range, criteria for high permeability, 
and definition of the dose used for the Do calculation [28]. One of the most significant differences is about 
the biowaiver for BCS class III drugs. WHO, European Union, and Canada accept biowaiver for BCS class III 
drugs which show very rapid dissolution (>85 % dissolution in 15 min), while only BCS class I drugs are 
eligible for biowaiver in the US FDA and Korea FDA guideline. However, there are several computer 
simulation and experimental studies on the biowaiver for BCS class III drugs, suggesting that BCS class III 
drugs are suitable for biowaiver [20,21,29-33]. In addition, it has been pointed out that many BCS class III 
drugs show BE even when the dissolution profiles are different between the test and reference drugs, for 
example famotidine, hydrochlorothiazide, and cimetidine [33,34]. Moreover, WHO adopts the possibility of 
biowaiver for BCS class IIa drugs with low solubility at acidic pH and high solubility at neutral pH that are 
absorbed completely. However, it was reported that, in the case of ibuprofen, the typically BCS class IIa 
drug, the BE of Cmax is more sensitive to the difference of dissolution rates [35,36].  
The BCS class distribution of ODTs and IR formulations may reflect their non-BE risk due to the 
difference of the dissolution rates. Based on the BCS-BWS, BE is most easily established for BCS class I 
drugs. However, no difference in the distribution of the BCS classes, including subclasses, between the 
ODTs and IR formulations was observed in this study. This result may suggest that a BCS class I drug would 
not necessarily be suitable to show BE. Ramirez et al. reported that in the 124 clinical BE studies there is no 
difference in the number of subjects in the BE study and the inter- and intra-subject variability for Cmax or 
AUC between four BCS classes [37]. All the BCS classes drugs have the risk of non-BE. Their results also 
showed that all of the bioinequivalent parameters in BCS class I drugs was Cmax, but not AUC. The results of 
the present study suggest that the elimination t1/2 would affect the success rate of a BE study more 
significantly than the BCS class of a drug (e.g. ibuprofen). 
In conclusion, drugs with a lower dose strength (<10 mg) and a longer elimination t1/2 (>6.5 h) were 
suggested to be more suitable for an ODT. However, the distributions of the ODT and IR formulation among 
each BCS class were similar, suggesting that the BCS classes are irrelevant to the development risk of ODTs.  
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Supplement Table 1. ODT drug list used in this study 
Drug Prescription information 
Acarbose http://www.info.pmda.go.jp/go/interview/1/630004_3969003F3037_1_005_1F 
Ambroxol hydrochloride http://www.info.pmda.go.jp/go/interview/1/300119_2239001G1039_1_061_1F 
Amlodipine besylate http://www.info.pmda.go.jp/go/interview/2/671450_2171022F1029_2_1F 
http://www.info.pmda.go.jp/go/interview/3/400093_2171022F1045_3_017_1F 
Aripiprazole http://www.info.pmda.go.jp/go/interview/1/180078_1179045F4022_1_012_1F 
Bepotastine besylate http://www.info.pmda.go.jp/go/interview/1/400315_4490022F3022_1_090_1F 
Bicalutamide http://www.info.pmda.go.jp/go/interview/1/670227_4291009F1039_1_171_1F 
Brotizolam http://www.info.pmda.go.jp/go/interview/1/650168_1124009F2025_1_14X_1F 
Cetirizine hydrochloride http://www.info.pmda.go.jp/go/interview/1/300119_4490020F1225_1_051_1F 
Cilostazol http://www.info.pmda.go.jp/go/interview/1/180078_3399002F3020_1_005_1F 
Desmopressin acetate hydrate http://www.info.pmda.go.jp/go/interview/1/670666_2419001F1023_2_1F 
Dienogest http://www.info.pmda.go.jp/go/interview/1/790005_2499010F1023_1_M02_1F 
Domperidone http://www.info.pmda.go.jp/go/interview/1/230124_2399005F3020_1_004_1F 
Donepezil hydrochloride http://www.info.pmda.go.jp/go/interview/1/170033_1190012F3029_1_028_1F 




Fexofenadine hydrochloride http://www.info.pmda.go.jp/go/interview/1/780069_4490023F1024_1_021_1F 






Irsogladine maleate http://www.info.pmda.go.jp/go/interview/1/530263_2329020F3020_1_05F_1F 
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Memantine hydrochloride http://www.info.pmda.go.jp/go/interview/1/430574_1190018F1023_1_M09_1F 




Olopatadine hydrochloride http://www.info.pmda.go.jp/go/interview/1/230124_4490025F3026_1_006_1F 
Ondansetron hydrochloride http://www.info.pmda.go.jp/go/interview/1/340278_2391006F1023_1_1F 
Oteracil potassium http://www.info.pmda.go.jp/go/interview/1/400107_4229101F1026_1_10E_1F 
Paroxetine hydrochloride hydrate http://www.info.pmda.go.jp/go/interview/1/480235_1179041F1254_1_005_1F 
Pioglitazone hydrochloride http://www.info.pmda.go.jp/go/interview/1/400256_3969007F3027_1_007_1F 
Pitavastatin calcium http://www.info.pmda.go.jp/go/interview/1/270072_2189016F4027_1_005_1F 
Polaprezinc http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/380077_2329027F1029_1_04 
Pramipexole hydrochloride hydrate http://www.info.pmda.go.jp/go/interview/1/480235_1169012F3025_1_004_1F 




Rizatriptan benzoate http://www.info.pmda.go.jp/go/interview/2/230109_2160006F1026_2_011_1F 
Selegiline hydrochloride http://www.info.pmda.go.jp/go/interview/1/170654_1169010F2020_1_S03_1F 
Sertraline hydrochloride http://www.info.pmda.go.jp/go/interview/2/671450_1179046F1028_2_1F 
Sildenafil citrate http://www.info.pmda.go.jp/go/interview/1/480235_259000AF3027_1_002_1F 
Solifenacin succinate http://www.info.pmda.go.jp/go/interview/1/800126_2590011F3020_1_1F 
Taltirelin hydrate http://www.info.pmda.go.jp/go/interview/1/400315_1190014F2021_1_050_1F 
Tamsulosin hydrochloride http://www.info.pmda.go.jp/go/interview/1/800126_2590008F1026_1_1F 
Tegafur http://www.info.pmda.go.jp/go/interview/1/400107_4229101F1026_1_10E_1F 
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Supplement Table 2. IR formulation drug list used in this study 
Drug Prescription information 
Acarbose http://www.info.pmda.go.jp/go/interview/1/630004_3969003F3037_1_005_1F 
Acetaminophen http://www.info.pmda.go.jp/go/interview/3/671610_1141007F1063_3_15L_1F 
Acetylsalicylic acid http://www.info.pmda.go.jp/go/interview/1/630004_3399007H1021_1_002_1F 
Acyclovir http://www.info.pmda.go.jp/go/interview/W/340278_6250002F1025_1_001_1F 
Alendronate sodium hydrate http://www.info.pmda.go.jp/go/interview/2/170050_3999018F1021_2_018_1F 
Alfacalcidol http://www.info.pmda.go.jp/go/interview/1/450045_3112001M1046_1_007_1F 
Allopurinol http://www.info.pmda.go.jp/go/interview/W/340278_3943001F1314_1_1F 
Ambroxol hydrochloride http://www.info.pmda.go.jp/go/interview/1/650168_2239001N1135_1_148_1F 
Amlodipine besylate http://www.info.pmda.go.jp/go/interview/2/671450_2171022F1029_2_1F 
Atenolol http://www.info.pmda.go.jp/go/interview/3/670227_2123011F1155_1_131_1F 
Atorvastatin calcium http://www.info.pmda.go.jp/go/interview/1/800126_2189015F1023_1_1F 
Azithromycin hydrate http://www.info.pmda.go.jp/go/interview/2/671450_6149004F1028_2_1F 
Azulene sulfonate http://www.info.pmda.go.jp/go/interview/1/530263_2323001F1225_1_04F_1F 
Benidipine hydrochloride http://www.info.pmda.go.jp/go/interview/1/230124_2171021F1024_1_001_1F 
Beraprost sodium http://www.info.pmda.go.jp/go/interview/1/480220_3399005F1021_1_A06_1F 
Bicalutamide http://www.info.pmda.go.jp/go/interview/1/670227_4291009F1039_1_171_1F 
Bisoprolol fumarate http://www.info.pmda.go.jp/go/interview/1/400315_2123016F1107_1_120_1F 
Brotizolam http://www.info.pmda.go.jp/go/interview/1/650168_1124009F2025_1_14X_1F 
Cabergoline http://www.info.pmda.go.jp/go/interview/4/671450_1169011F1028_4_1F 
Camostat mesylate http://www.info.pmda.go.jp/go/interview/1/180188_3999003F1297_1_005_1F 
Candesartan cilexetil http://www.info.pmda.go.jp/go/interview/1/400256_2149040F1026_1_004_1F 
Carvedilol http://www.info.pmda.go.jp/go/interview/2/430574_2149032F1021_2_A13_1F 
Cefcapene pivoxil hydrochloride http://www.info.pmda.go.jp/go/interview/1/340018_6132016F1023_1_011_1F 
Cefdinir http://www.info.pmda.go.jp/go/interview/3/800126_6132013M1029_3_1F 
Cefditoren pivoxil http://www.info.pmda.go.jp/go/interview/1/780009_6132015F1037_1_01A_1F 
Cefotiam hexetil hydrochloride http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400256_6132012F1025_1_12 
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Cetirizine hydrochloride http://www.info.pmda.go.jp/go/interview/2/820110_4490020F1020_2_013_1F 
Cilostazol http://www.info.pmda.go.jp/go/interview/1/180078_3399002F3020_1_005_1F 
Clarithromycin http://www.info.pmda.go.jp/go/interview/1/400059_6149003F2038_1_028_1F 
Cyclosporin a http://www.info.pmda.go.jp/go/interview/2/300242_3999004M3021_2_NEO_1F 
Diclofenac sodium http://www.info.pmda.go.jp/go/interview/1/300242_1147002F1560_1_VOL_1F 
Donepezil hydrochloride http://www.info.pmda.go.jp/go/interview/1/170033_1190012F3029_1_028_1F 
Doxazosin mesylate http://www.info.pmda.go.jp/go/interview/2/671450_2149026F1026_2_1F 
Doxifluridine http://www.info.pmda.go.jp/go/interview/2/450045_4223004M1027_2_004_1F 
Ebastine http://www.info.pmda.go.jp/go/interview/1/400093_4490019F1028_1_018_1F 
Enalapril maleate http://www.info.pmda.go.jp/go/interview/2/170050_2144002F1024_2_016_1F 
Epalrestat http://www.info.pmda.go.jp/go/interview/1/180188_3999013F1231_1_004_1F 
Eperisone hydrochloride http://www.info.pmda.go.jp/go/interview/1/170033_1249009D1030_1_007_1F 
Epinastine hydrochloride http://www.info.pmda.go.jp/go/interview/1/650168_4490014F1025_1_119_1F 
Ethyl icosapentate http://www.info.pmda.go.jp/go/interview/1/790005_3399004M2022_1_M03_1F 
Etizolam http://www.info.pmda.go.jp/go/interview/2/400315_1179025C1054_2_150_1F 
Famotidine http://www.info.pmda.go.jp/go/interview/1/800126_2325003F1024_1_1F 
Fexofenadine hydrochloride http://www.info.pmda.go.jp/go/interview/1/780069_4490023F1024_1_021_1F 
Fluconazole http://www.info.pmda.go.jp/go/interview/2/671450_6290002M1020_2_1F 
Flurbiprofen http://www.info.pmda.go.jp/go/interview/1/200022_1149011D1032_1_080_1F 
Fluvastatin sodium http://www.info.pmda.go.jp/go/interview/3/300242_2189012F1020_3_LOC_1F 




Granisetron hydrochloride http://www.info.pmda.go.jp/go/interview/1/450045_2391002C1037_1_010_1F 
Imatinib mesylate http://www.info.pmda.go.jp/go/interview/1/300242_4291011F1028_1_GLI_1F 
Imidapril hydrochloride http://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F 
Itraconazole http://www.info.pmda.go.jp/go/interview/1/800155_6290004M1029_2_008_1F 
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Ketoprofen a http://www.info.pmda.go.jp/go/interview/2/650208_1149700J1035_2_1F 
Ketotifen fumarate http://www.info.pmda.go.jp/go/interview/1/300242_4490003M1263_1_Z-C_1F 
L-carbocysteine http://www.info.pmda.go.jp/go/interview/1/230109_2233002F1174_1_001_1F 
Levofloxacin http://www.info.pmda.go.jp/go/interview/1/430574_6241013C2024_1_c11_1F 
Limaprost alfadex http://www.info.pmda.go.jp/go/interview/1/180188_3399003F1073_1_010_1F 
Loratadine http://www.info.pmda.go.jp/go/interview/1/170050_4490027F1022_1_015_1F 
Losartan potassium http://www.info.pmda.go.jp/go/interview/2/170050_2149039F1031_2_018_1F 
Loxoprofen sodium hydrate http://www.info.pmda.go.jp/go/interview/1/430574_1149019C1149_1_LO8_1F 








Mexiletine hydrochloride http://www.info.pmda.go.jp/go/interview/1/650168_2129003M1021_1_14Y_1F 
Montelukast sodium http://www.info.pmda.go.jp/go/interview/1/230109_4490026F2040_1_035_1F. 
Mosapride citrate hydrate http://www.info.pmda.go.jp/go/interview/1/400093_2399010B1034_1_020_1F 







Olopatadine hydrochloride http://www.info.pmda.go.jp/go/interview/1/230124_4490025F3026_1_006_1F 
Oseltamivir phosphate http://www.info.pmda.go.jp/go/interview/1/450045_6250021M1027_1_026_1F 
Paroxetine hydrochloride hydrate http://www.info.pmda.go.jp/go/interview/2/340278_1179041F1025_1_018_1F 
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Pergolide mesylate http://www.info.pmda.go.jp/go/interview/2/230124_1169008F1026_2_004_1F 
Perindopril erbumine http://www.info.pmda.go.jp/go/interview/3/230124_2144012F1028_3_001_1F 
Pilsicainide hydrochloride hydrate http://www.info.pmda.go.jp/go/interview/3/430574_2129008M1024_3_S10_1F 
Pioglitazone hydrochloride http://www.info.pmda.go.jp/go/interview/1/400256_3969007F3027_1_007_1F 
Pranlukast hydrate http://www.info.pmda.go.jp/go/interview/1/180188_4490017M1036_1_009_1F 
Pravastatin sodium http://www.info.pmda.go.jp/go/interview/2/430574_2189010C1032_2_M10_1F 
Procaterol hydrochloride hydrate http://www.info.pmda.go.jp/go/interview/1/180078_2259004F2168_1_005_1F 
Propiverine hydrochloride http://www.info.pmda.go.jp/go/interview/1/400107_2590007C1025_1_04L_1F 
Quetiapine fumarate http://www.info.pmda.go.jp/go/interview/2/800126_1179042C1023_2_1F 
Ranitidine hydrochloride http://www.info.pmda.go.jp/go/interview/1/340278_2325002F1194_1_009_1F 
Rebamipide http://www.info.pmda.go.jp/go/interview/1/180078_2329021D1020_1_013_1F 
Risedronate sodium hydrate http://www.info.pmda.go.jp/go/interview/2/111890_3999019F1026_2_016_1F 
Risperidone http://www.info.pmda.go.jp/go/interview/1/800155_1179038F5029_1_005_1F 
Sarpogrelate hydrochloride http://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_15A_1F 
Simvastatin http://www.info.pmda.go.jp/go/interview/2/170050_2189011F1025_2_022_1F 
Sultamicillin tosilate hydrate http://www.info.pmda.go.jp/go/interview/2/671450_6131008F1030_2_1F 
Tacrolimus hydrate http://www.info.pmda.go.jp/go/interview/3/800126_3999014D1022_3_1F 
Taltirelin hydrate http://www.info.pmda.go.jp/go/interview/1/400315_1190014F2021_1_050_1F 
Tamoxifen citrate http://www.info.pmda.go.jp/go/interview/1/670227_4291003F1163_1_012_1F 
Tegafur http://www.info.pmda.go.jp/go/interview/1/400107_4229101F1026_1_10E_1F 
Temocapril hydrochloride http://www.info.pmda.go.jp/go/interview/3/430574_2144009F1026_3_C10_1F 
Teprenone http://www.info.pmda.go.jp/go/interview/1/170033_2329012C1026_1_009_1F 
Terbinafine hydrochloride http://www.info.pmda.go.jp/go/interview/1/730012_6290005F1032_1_006_1F 
Ticlopidine hydrochloride http://www.info.pmda.go.jp/go/interview/4/780069_3399001C1027_4_011_1F 
Tocopherol nicotinate http://www.info.pmda.go.jp/go/interview/1/170033_2190006C1037_1_008_1F 
Tulobuterol hydrochloride http://www.info.pmda.go.jp/go/interview/3/100159_2259002F1065_3_004_1F 
Ursodeoxycholic acid http://www.info.pmda.go.jp/go/interview/2/400315_2362001F1088_2_11A_1F 
Valacyclovir hydrochloride http://www.info.pmda.go.jp/go/interview/1/340278_6250019F1020_1_013_1F 
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Valproate sodium http://www.info.pmda.go.jp/go/interview/1/230124_1139004F1096_1_005_1F 
Valsartan http://www.info.pmda.go.jp/go/interview/1/300242_2149041F5026_5_DIO_1F 
Voglibose http://www.info.pmda.go.jp/go/interview/1/400256_3969004F3023_1_006_1F 
Zolpidem tartrate http://www.info.pmda.go.jp/go/interview/3/800126_1129009F1025_3_1F 
a
 IR formulations of ketoprofen are no longer in production in Japan. The dose strengths of the IR formulations were from the FDA website 
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm). 
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Supplement Table 3. Model equation for NC calculation by using the Henderson-Hasselbalch equation. 
Compound type Model equation 








Di acid NC =  
(−1) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐻 + (−2) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2
[10−𝑝𝐻]2 + 10−𝑝𝐾𝑎1 × 10−𝑝𝐻+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2
 
Di base NC =  
2 × [10−𝑝𝐻]2 + 10−𝑝𝐾𝑎1 × 10−𝑝𝐻
[10−𝑝𝐻]2 + 10−𝑝𝐾𝑎1 × 10−𝑝𝐻+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2
 
Mono acid/mono base NC =  
[10−𝑝𝐻]2 + (−1) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2




(−1) × 10−𝑝𝐾𝑎1 × [10−𝑝𝐻]2 + (−2) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐻 + (−3) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐾𝑎3
[10−𝑝𝐻]3 + 10−𝑝𝐾𝑎1 × [10−𝑝𝐻]2+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐻+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐾𝑎3
 
Tri base NC =  
3 × [10−𝑝𝐻]3 + 2 × 10−𝑝𝐾𝑎1 × [10−𝑝𝐻]2 + 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐻
[10−𝑝𝐻]3 + 10−𝑝𝐾𝑎1 × [10−𝑝𝐻]2+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐻+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐾𝑎3
 
Di acid/mono base NC =  
[10−𝑝𝐻]3 + (−1) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐻+(−2) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐾𝑎3
[10−𝑝𝐻]3 + 10−𝑝𝐾𝑎1 × [10−𝑝𝐻]2+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐻+10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐾𝑎3
 
Mono acid/di base NC =  
2 × [10−𝑝𝐻]3 + 10−𝑝𝐾𝑎1 × [10−𝑝𝐻]2 + (−1) × 10−𝑝𝐾𝑎1 × 10−𝑝𝐾𝑎2 × 10−𝑝𝐾𝑎3
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Supplement Table 4 Solubility Definitions 
Solubility 
definition 
Parts of solvent required for 1 





very soluble <1 ≥1000 1000 
freely soluble 1‐10 100‐1000 100 
soluble 10‐30 33‐100 33 
sparingly soluble 30‐100 10‐33 10 
slightly soluble 100‐1000 1‐10 1 
very slightly 
soluble 
1000‐10000 0.1-1 0.1 
practically 
insoluble 
≥10000 <0.1 0.01 
 
 
 
